Imaging in multiple system atrophy

Neurology and Clinical Neuroscience

Volumn 2, Issue 6, 2014, Pages 178-187

  Chandran, Vijay ^a   Stoessl, A Jon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cardiac scintigraphy; Diffusion weighted imaging; Iron imaging; Magnetic resonance imaging; Positron emission tomography

Indexed keywords

DOPAMINE 2 RECEPTOR;

ATAXIA; CARDIAC IMAGING; DIFFUSION WEIGHTED IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; MAGNETIC RESONANCE VOLUMETRY; NERVOUS SYSTEM INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUSCEPTIBILITY WEIGHTED IMAGING; VOLUMETRY;

EID: 84931007795     PISSN: None     EISSN: 20494173     Source Type: Journal    
DOI: 10.1111/ncn3.125     Document Type: Review

References (86)

1. Quinn N. Multiple system atrophy-the nature of the beast. J. Neurol. Neurosurg. Psychiatry 1989; 52(suppl): 78-89.
2. Gilman S, Wenning GK, Low PA et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008; 71: 670-6.
3. Ozawa T, Paviour D, Quinn NP et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain. 2004; 127: 2657-71.
4. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J. Neurol. Sci. 1989; 94: 79-100.
5. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 1998; 251: 205-8.
6. Osaki Y, Ben-Shlomo Y, Lees AJ, Wenning GK, Quinn NP. A validation exercise on the new consensus criteria for multiple system atrophy. Mov. Disord. 2009; 24: 2272-6.
7. Schrag A, Kingsley D, Phatouros C et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 1998; 65: 65-71.
8. Matsusue E, Fujii S, Kanasaki Y et al. Putaminal lesion in multiple system atrophy: postmortem MR-pathological correlations. Neuroradiology 2008; 50: 559-67.
9. Matsusue E, Fujii S, Kanasaki Y, Kaminou T, Ohama E, Ogawa T. Cerebellar lesions in multiple system atrophy: postmortem MR imaging-pathologic correlations. AJNR Am. J. Neuroradiol. 2009; 30: 1725-30.
10. Fujii S, Matsusue E, Kinoshita T, Sugihara S, Ohama E, Ogawa T. Hyperintense putaminal rim at 3T reflects fewer ferritin deposits in the lateral marginal area of the putamen. AJNR Am. J. Neuroradiol. 2007; 28: 777-81.
11. Tha KK, Terae S, Tsukahara A et al. Hyperintense putaminal rim at 1.5 T: prevalence in normal subjects and distinguishing features from multiple system atrophy. BMC Neurol. 2012; 12: 39.
12. Horimoto Y, Aiba I, Yasuda T et al. Longitudinal MRI study of multiple system atrophy - when do the findings appear, and what is the course? J. Neurol. 2002; 249: 847-54.
13. Meijer FJ, Aerts MB, Abdo WF et al. Contribution of routine brain MRI to the differential diagnosis of parkinsonism: a 3-year prospective follow-up study. J. Neurol. 2012; 259: 929-35.
14. Massey LA, Micallef C, Paviour DC et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov. Disord. 2012; 27: 1754-62.
15. Martin WR, Ye FQ, Allen PS. Increasing striatal iron content associated with normal aging. Mov. Disord. 1998; 13: 281-6.
16. Bartzokis G, Tishler TA, Lu PH et al. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol. Aging 2007; 28: 414-23.
17. Vymazal J, Righini A, Brooks RA et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 1999; 211: 489-95.
18. Haacke EM, Xu Y, Cheng YC, Reichenbach JR. Susceptibility weighted imaging (SWI). Magn. Reson. Med. 2004; 52: 612-8.
19. Gupta D, Saini J, Kesavadas C et al. Utility of susceptibility-weighted MRI in differentiating Parkinson's disease and atypical parkinsonism. Neuroradiology 2010; 52: 1087-94.
20. Wang Y, Butros SR, Shuai X et al. Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am. J. Neuroradiol. 2012; 33: 266-73.
21. Schulz JB, Skalej M, Wedekind D et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann. Neurol. 1999; 45: 65-74.
22. Nicoletti G, Fera F, Condino F et al. MR imaging of middle cerebellar peduncle width: differentiation of multiple system atrophy from Parkinson's disease. Radiology 2006; 239: 825-30.
23. Le Bihan D, Turner R, Douek P, Patronas N. Diffusion MR imaging: clinical applications. AJR Am. J. Roentgenol. 1992; 159: 591-9.
24. Schocke MF, Seppi K, Esterhammer R et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology. 2002; 58: 575-80.
25. Seppi K, Schocke MF, Esterhammer R et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology. 2003; 60: 922-7.
26. Nicoletti G, Lodi R, Condino F et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain. 2006; 129: 2679-87.
27. Paviour DC, Thornton JS, Lees AJ, Jäger HR. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy. Mov. Disord. 2007; 22: 68-74.
28. Kanazawa M, Shimohata T, Terajima K et al. Quantitative evaluation of brainstem involvement in multiple system atrophy by diffusion-weighted MR imaging. J. Neurol. 2004; 251: 1121-4.
29. Shiga K, Yamada K, Yoshikawa K, Mizuno T, Nishimura T, Nakagawa M. Local tissue anisotropy decreases in cerebellopetal fibers and pyramidal tract in multiple system atrophy. J. Neurol. 2005; 252: 589-96.
30. Oishi K, Konishi J, Mori S et al. Reduced fractional anisotropy in early-stage cerebellar variant of multiple system atrophy. J. Neuroimaging 2009; 19: 127-31.
31. Seppi K, Schocke MF, Mair KJ et al. Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. Neuroimage. 2006; 31: 240-5.
32. Pellecchia MT, Barone P, Vicidomini C et al. Progression of striatal and extrastriatal degeneration in multiple system atrophy: a longitudinal diffusion-weighted MR study. Mov. Disord. 2011; 26: 1303-9.
33. Wang PS, Wu HM, Lin CP, Soong BW. Use of diffusion tensor imaging to identify similarities and differences between cerebellar and Parkinsonism forms of multiple system atrophy. Neuroradiology 2011; 53: 471-81.
34. Pellecchia MT, Barone P, Mollica C et al. Diffusion-weighted imaging in multiple system atrophy: a comparison between clinical subtypes. Mov. Disord. 2009; 24: 689-96.
35. Davie CA, Wenning GK, Barker GJ et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann. Neurol. 1995; 37: 204-10.
36. Federico F, Simone IL, Lucivero V et al. Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders. Mov. Disord. 1997; 12: 903-9.
37. Watanabe H, Fukatsu H, Katsuno M et al. Multiple regional 1HMR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker. J. Neurol. Neurosurg. Psychiatry 2004; 75: 103-9.
38. Takado Y, Igarashi H, Terajima K et al. Brainstem metabolites in multiple system atrophy of cerebellar type: 3.0-T magnetic resonance spectroscopy study. Mov. Disord. 2011; 26: 1297-302.
39. DeVolder AG, Francart J, Laterre C et al. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann. Neurol. 1989; 26: 239-47.
40. Gilman S, Markel DS, Koeppe RA et al. Cerebellar and brain-stem hypometabolism in olivopontocerebellar atrophy detected with positron emission tomography. Ann. Neurol. 1988; 23: 223-30.
41. Eidelberg D, Takikawa S, Moeller JR et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann. Neurol. 1993; 33: 518-27.
42. Perani D, Bressi S, Testa D et al. Clinical/metabolic correlations in multiple system atrophy: a fludeoxyglucose F 18 positron emission tomographic study. Arch. Neurol. 1995; 52: 179-85.
43. Taniwaki T, Nakagawa M, Yamada T et al. Cerebral metabolic changes in early multiple system atrophy: a PET study. J. Neurol. Sci. 2002; 200: 79-84.
44. Lyoo CH, Jeong Y, Ryu YH et al. Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy. Brain. 2008; 131: 438-46.
45. Lee PH, An YS, Yong SW, Yoon SN. Cortical metabolic changes in the cerebellar variant of multiple system atrophy: a voxel-based FDG-PET study in 41 patients. Neuroimage. 2008; 40: 796-801.
46. Brooks DJ, Ibanez V, Sawle GV et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with [11C]raclopride and positron emission tomography. Ann. Neurol. 1992; 31: 184-92.
47. Sawle GV, Playford ED, Brooks DJ, Quinn N, Frackowiak RSJ. Asymmetrical pre-synaptic and post-synaptic changes in the striatal dopamine projection in dopa naive parkinsonism. Brain 1993; 116: 853-67.
48. Brooks DJ, Ibanez V, Sawle GV et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann. Neurol. 1990; 28: 547-55.
49. Lewis SJ, Pavese N, Rivero-Bosch M et al. Brain monoamine systems in multiple system atrophy: a positron emission tomography study. Neurobiol. Dis. 2012; 46: 130-6.
50. Hirano S, Shinotoh H, Arai K et al. PET study of brain acetylcholinesterase in cerebellar degenerative disorders. Mov. Disord. 2008; 23: 1154-60.
51. Gilman S, Chervin RD, Koeppe RA et al. Obstructive sleep apnea is related to a thalamic cholinergic deficit in MSA. Neurology. 2003; 61: 35-9.
52. Gilman S, Koeppe RA, Chervin RD et al. REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA. Neurology. 2003; 61: 29-34.
53. Antonini A, Leenders KL, Vontobel P et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain. 1997; 120: 2187-95.
54. Eckert T, Barnes A, Dhawan V et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005; 26: 912-21.
55. Eckert T, Tang C, Ma Y et al. Abnormal metabolic networks in atypical parkinsonism. Mov. Disord. 2008; 23: 727-33.
56. Poston KL, Tang CC, Eckert T et al. Network correlates of disease severity in multiple system atrophy. Neurology. 2012; 78: 1237-44.
57. Kikuchi A, Takeda A, Okamura N et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain. 2010; 133: 1772-8.
58. Kudo Y, Okamura N, Furumoto S et al. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J. Nucl. Med. 2007; 48: 553-61.
59. Fodero-Tavoletti MT, Mulligan RS, Okamura N et al. In vitro characterisation of BF227 binding to alphasynuclein/Lewy bodies. Eur. J. Pharmacol. 2009; 617: 54-8.
60. Gerhard A, Banati RB, Goerres GB et al. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology. 2003; 61: 686-9.
61. Brücke T, Asenbaum S, Pirker W et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I]b-CIT and SPECT: correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J. Neural Transm. Suppl. 1997; 50: 9-24.
62. Kim G, Kim S, Lee W. Preclinical impairment of the striatal dopamine transporter system in sporadic olivopontocerebellar atrophy: studied with [123I]b-CIT and SPECT. Eur. Neurol. 2000; 43: 23-9.
63. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [(123)I] beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. MovDisord. 2001; 16: 1023-32.
64. Pirker W, Asenbaum S, Bencsits G et al. [I-123]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov. Disord. 2000; 15: 1158-67.
65. Pirker W, Djamshidian S, Asenbaum S et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov. Disord. 2002; 17: 45-53.
66. Scherfler C, Seppi K, Donnemiller E et al. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain. 2005; 128: 1605-12.
67. Nocker M, Seppi K, Donnemiller E et al. Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT. Eur. J. Nucl. Med. Mol. Imaging. 2012; 39: 1012-20.
68. Hakusui S, Yasuda T, Yanagi T et al. A radiological analysis of heart sympathetic functions with meta-[123I] iodobenzylguanidine in neurological patients with autonomic failure. J. Auton. Nerv. Syst. 1994; 49: 81-4.
69. Wieland DM, Brown LE, Rogers WL et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J. Nucl. Med. 1981; 22: 22-31.
70. Treglia G, Stefanelli A, Cason E, Cocciolillo F, Di Giuda D, Giordano A. Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson's disease and multiple-system atrophy: a systematic review and a meta-analysis. Clin. Neurol. Neurosurg. 2011; 113: 823-9.
71. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1999; 67: 189-94.
72. Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology. 1999; 53: 1020-5.
73. Courbon F, Brefel-Courbon C, Thalamas C et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov. Disord. 2003; 18: 890-7.
74. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2005; 76: 249-51.
75. Druschky A, Hilz MJ, Platsch G et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J. Neurol. Sci. 2000; 175: 3-12.
76. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J. Neurol. Sci. 1998; 155: 60-7.
77. Taki J, Nakajima K, Hwang EH et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur. J. Nucl. Med. 2000; 27: 566-73.
78. Nagayama H, Ueda M, Yamazaki M, Nishiyama Y, Hamamoto M, Katayama Y. Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov. Disord. 2010; 25: 1744-7.
79. Sone M, Yoshida M, Hashizume Y, Hishikawa N, Sobue G. Alpha-synuclein-immunoreactive structure formation is enhanced in sympathetic ganglia of patients with multiple system atrophy. Acta Neuropathol. 2005; 110: 19-26.
80. Orimo S, Kanazawa T, Nakamura A et al. Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol. 2007; 113: 81-6.
81. Nishie M, Mori F, Fujiwara H et al. Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol. 2004; 107: 292-8.
82. Chung EJ, Lee WY, Yoon WT, Kim BJ, Lee GH. MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy. Mov. Disord. 2009; 24: 1650-5.
83. Orimo S, Suzuki M, Inaba A, Mizusawa H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat. Disord. 2012; 18: 494-500.
84. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J. Neurol. Neurosurg. Psychiatry 2002; 73: 517-23.
85. Köllensperger M, Seppi K, Liener C et al. Diffusion weighted imaging best discriminates PD from MSA-P: a comparison with tilt table testing and heart MIBG scintigraphy. Mov. Disord. 2007; 22: 1771-6.
86. Umemura A, Oeda T, Hayashi R et al. Diagnostic accuracy of apparent diffusion coefficient and 123I-metaiodobenzylguanidine for differentiation of multiple system atrophy and Parkinson's disease. PLoS ONE 2013; 8: e61066.